Kerry Group’s Botanical Extract Study: A Potential Game-Changer for Sleep Disorders

Kerry Group plc ((GB:KYGA)) announced an update on their ongoing clinical study.

Study Overview: Kerry Group plc is conducting a clinical study titled ‘A Prospective, Randomized, Double Blind, Placebo Controlled Study To Evaluate The Effects Of Ashwagandha (Withania Somnifera, Ws) Root Plus Leaf Aqueous Extract On Quality Of Sleep In Subjects With Non-Restorative Sleep.’ The study aims to assess whether a botanical extract can improve sleep quality and alleviate symptoms of non-restorative sleep in healthy adults, a condition that affects many and impacts daily functioning.

Intervention/Treatment: The study tests a botanical extract derived from Ashwagandha, administered in three different doses (125 mg, 250 mg, and 500 mg) compared to a placebo. The extract is intended to enhance sleep quality and reduce non-restorative sleep symptoms.

Study Design: This is an interventional study with a randomized, parallel assignment model. Participants are randomly assigned to one of four groups, receiving either a dose of the botanical extract or a placebo. The study employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the group assignments. The primary aim is to evaluate the extract’s effectiveness on sleep quality.

Study Timeline: The study began on July 10, 2025, with the latest update on August 25, 2025. These dates are crucial as they indicate the study’s progress and current status, which is still recruiting participants.

Market Implications: The outcome of this study could significantly impact Kerry Group’s stock performance, as positive results may enhance investor confidence and market position in the health and wellness sector. Competitors in the dietary supplement industry will likely monitor these developments closely, as successful results could shift market dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.